EP Patent

EP0505108B1 — Compositions for regulating skin wrinkles comprising an Arg-Ser-Arg-Lys based peptide

Assigned to Procter and Gamble Co · Expires 1995-10-18 · 31y expired

What this patent protects

Patent listed against Dovonex.

Drugs covered by this patent

Dovonex (CALCIPOTRIENE)

Patent Metadata

Patent number: EP0505108B1
Jurisdiction: EP
Classification: —
Expires: 1995-10-18
Drug substance claim: No
Drug product claim: No
Assignee: Procter and Gamble Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.